The study of plasma and urine proteomic profiles in patients with ischemic brain injury is important to better understanding of the mechanisms by which thrombolytic agents or other therapy affects clinical outcomes. The purpose of this study is to study the proteomic profile of patients with ischemic brain injury and compare it to control subjects without ischemic brain injury, subjects with other chronic neurologic diseases or systemic vascular diseases, and pre- and post- therapy which may be associated with, or predictive of, therapeutic outcome.
The investigators hypothesize that there is a unique set of proteins expressed in serum and urine in patients with ischemic brain injury that may provide a more complete understanding of ischemic brain injury pathophysiology.
Ultimately, this study may provide information of direct relevance to the medical care of a large proportion of patients with ischemic brain injury and other neurologic diseases in the future. And proteomic proteomic profile may provide important information about the roles of specific biomarkers. Perhaps the prevention of ischemic injury related complications.
- Ischemic Brain Injury
- Healthy Individual
- Patent Foramen Ovale (PFO)
- Neurovascular Injury
- Observation: Cohort
- Perspective: Prospective
- Sampling: Non-Probability Sample
Adult with acute ischemic brain injury, adults with neurological or vascular conditions other than acute stroke and healthy adults.
|Type||Measure||Time Frame||Safety Issue|
|Primary||In patients treated w/ thrombolytic agents/other therapy, the plasma/urine proteomic profiles will differ between pre- & post-therapy, indicating a characteristic therapy-induced state, which may be associated with/predictive of, therapeutic outcome.||5 years||No|
|Primary||Clinical Outcome and Biomarker Outcome|